Pursuant to the deal, Sanofi gains license to develop an immunotherapy to stop immune responses provoked by a food allergen.
Sanofi also has a choice to develop two other immunotherapeutic candidates individually targeting a specific food or aeroallergen.
Novel therapies are then engineered using Selecta’s Synthetic Vaccine Particle (SVP) platform to produce immune tolerance for two additional antigens by balancing the overactive response.
Selecta president and CEO Werner Cautreels said its SVP technology produces immune tolerance to specific antigens and restore balance to dysregulated immune systems.
"Our approach addresses the underlying causes of these diseases and thereby makes advances beyond today’s symptomatic treatments and allergen avoidance strategies," Cautreels added.
As per the agreement, Selecta will earn pre-clinical, clinical, regulatory and sales milestones worth $300m besides tiered royalties on US net sales for each of the three allergen indications considered in the deal.